The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Cardiotoxicity
A broad term often representing life-threatening scenarios including myocarditis, dysrhythmias, ventricular tachycardia, conduction abnormalities, heart failure, and/or valvular heart disease (PMID 29912044, 29980467)
Publications
Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis.
Translational oncology 2022 Mar 03;19;101383 — 2022 Mar 03 — 101383
Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.
The Lancet. Oncology 2018 12;19;1579-1589 — 2018 12 — 1579-1589
Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area.
The Canadian journal of cardiology 2018 08;34;1059-1068 — 2018 08 — 1059-1068
Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management.
Current oncology reports 2018 04 11;20;44 — 2018 04 11 — 44
Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.
Journal for immunotherapy of cancer 2016;4;50 — 2016 — 50